Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers / Shilpa Raval, Parva Jani, Pravin Patil, Parth Thakkar, Krutika Sawant
Aim:The work describes enhanced bioavailability of paliperidone palmitate through transdermal delivery using nanostructured lipid carriers (NLC).Materials & methods:NLCs were formulated by nanoprecipitation method followed by incorporation in transdermal patch and physicochemical characterization.Results:NLCs showed high percentage entrapment efficiency of 83.44 ± 0.8%, drug loading of 24.75 ± 1.10% (w/w), particle size of 173.8 ± 3.25 nm, polydispersity index of 0.143 ± 0.05 and zeta potential of -15.9 ± 0.75 mV.In vitroandex vivostudies indicated zero-order controlled drug release from NLCs and transdermal patch up to 48 h. Pharmacokinetic studies indicated 1.76-fold enhanced bioavailability by transdermal route as compared with oral drug delivery.Conclusion:From the results, it was concluded that drug-loaded NLCs-transdermal patch is promising drug delivery system for poorly bioavailable drugs. Aim: Materials & methods: Results: In vitro ex vivo Conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raval, Shilpa [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Bioavailability |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.4155/tde-2021-0036 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011092394 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011092394 | ||
| 003 | DE-627 | ||
| 005 | 20230713210628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0036 |2 doi | |
| 035 | |a (DE-627)KFL011092394 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2021-0036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Raval, Shilpa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers |c Shilpa Raval, Parva Jani, Pravin Patil, Parth Thakkar, Krutika Sawant |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:The work describes enhanced bioavailability of paliperidone palmitate through transdermal delivery using nanostructured lipid carriers (NLC).Materials & methods:NLCs were formulated by nanoprecipitation method followed by incorporation in transdermal patch and physicochemical characterization.Results:NLCs showed high percentage entrapment efficiency of 83.44 ± 0.8%, drug loading of 24.75 ± 1.10% (w/w), particle size of 173.8 ± 3.25 nm, polydispersity index of 0.143 ± 0.05 and zeta potential of -15.9 ± 0.75 mV.In vitroandex vivostudies indicated zero-order controlled drug release from NLCs and transdermal patch up to 48 h. Pharmacokinetic studies indicated 1.76-fold enhanced bioavailability by transdermal route as compared with oral drug delivery.Conclusion:From the results, it was concluded that drug-loaded NLCs-transdermal patch is promising drug delivery system for poorly bioavailable drugs. Aim: Materials & methods: Results: In vitro ex vivo Conclusion | ||
| 653 | |a bioavailability | ||
| 653 | |a nanostructured lipid carriers | ||
| 653 | |a paliperidone palmitate | ||
| 653 | |a schizophrenia | ||
| 653 | |a transdermal | ||
| 700 | 1 | |a Jani, Parva |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Pravin |e verfasserin |4 aut | |
| 700 | 1 | |a Thakkar, Parth |e verfasserin |4 aut | |
| 700 | 1 | |a Sawant, Krutika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2021-0036 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||